Literature DB >> 9882298

Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2).

M Cayabyab1, G B Karlsson, B A Etemad-Moghadam, W Hofmann, T Steenbeke, M Halloran, J W Fanton, M K Axthelm, N L Letvin, J G Sodroski.   

Abstract

In vivo passage of a poorly replicating, nonpathogenic simian-human immunodeficiency virus (SHIV-HXBc2) generated an efficiently replicating virus, KU-1, that caused rapid CD4(+) T-lymphocyte depletion and AIDS-like illness in monkeys (S. V. Joag, Z. Li, L. Foresman, E. B. Stephens, L.-J. Zhao, I. Adany, D. M. Pinson, H. M. McClure, and O. Narayan, J. Virol. 70:3189-3197, 1996). The env gene of the KU-1 virus was used to create a molecularly cloned virus, SHIV-HXBc2P 3.2, that differed from a nonpathogenic SHIV-HXBc2 virus in only 12 envelope glycoprotein residues. SHIV-HXBc2P 3.2 replicated efficiently and caused rapid and persistent CD4(+) T-lymphocyte depletion in inoculated rhesus macaques. Compared with the envelope glycoproteins of the parental SHIV-HXBc2, the SHIV-HXBc2P 3.2 envelope glycoproteins supported more efficient infection of rhesus monkey peripheral blood mononuclear cells. Both the parental SHIV-HXBc2 and the pathogenic SHIV-HXBc2P 3.2 used CXCR4 but none of the other seven transmembrane segment receptors tested as a second receptor. Compared with the parental virus, viruses with the SHIV-HXBc2P 3.2 envelope glycoproteins were more resistant to neutralization by soluble CD4 and antibodies. Thus, changes in the envelope glycoproteins account for the ability of the passaged virus to deplete CD4(+) T lymphocytes rapidly and specify increased replicative capacity and resistance to neutralization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882298      PMCID: PMC103917     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Persistent infection of macaques with simian-human immunodeficiency viruses.

Authors:  J T Li; M Halloran; C I Lord; A Watson; J Ranchalis; M Fung; N L Letvin; J G Sodroski
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

2.  Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.

Authors:  L Stamatatos; A Werner; C Cheng-Mayer
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism.

Authors:  N E Sharpless; W A O'Brien; E Verdin; C V Kufta; I S Chen; M Dubois-Dalcq
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  M Thali; C Furman; D D Ho; J Robinson; S Tilley; A Pinter; J Sodroski
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

5.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

6.  Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.

Authors:  M Thali; M Charles; C Furman; L Cavacini; M Posner; J Robinson; J Sodroski
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.

Authors:  M R Posner; L A Cavacini; C L Emes; J Power; R Byrn
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-01

9.  Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.

Authors:  A Koito; G Harrowe; J A Levy; C Cheng-Mayer
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  39 in total

1.  Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro.

Authors:  S Giannecchini; D Matteucci; A Ferrari; M Pistello; M Bendinelli
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Evolution of two amino acid positions governing broad neutralization resistance in a strain of feline immunodeficiency virus over 7 years of persistence in cats.

Authors:  Mauro Pistello; Donatella Matteucci; Simone Giannecchini; Francesca Bonci; Olimpia Sichi; Silvano Presciuttini; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

6.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

7.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

9.  Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.

Authors:  Anjali Joshi; Raphael T C Lee; Jonathan Mohl; Melina Sedano; Wei Xin Khong; Oon Tek Ng; Sebastian Maurer-Stroh; Himanshu Garg
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

10.  UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Authors:  Bart G Jones; Robert E Sealy; Xiaoyan Zhan; Pamela J Freiden; Sherri L Surman; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.